1 |
Ferlay J, Bray F, Pisani P, et al (2000). Globocan 2000: cancer incidence, mortality and prevalence worldwide. Lyon: International Agency for Research on Cancer.
|
2 |
Food and Drug Administration (FDA) \FDA News: FDA Licenses New Vaccine for Prevention of Cervical Cancer and Other Diseases in Females Caused by Human Papillomavirus.
|
3 |
Giuliano AR, Papenfuss M (2001). Human papillomavirus infection at the United States - Mexico border : implications for cervical cancer prevention and control. Cancer Epidemiol Biomarkers Prevent, 10, 1129-36.
|
4 |
Lorincz A, Reid R, Jenson A, et al (1992). Human papillomavirus infection of the cervix: relative risk associations of 15 common anogenital types. Obstetrics Gynecol, 79, 328-37.
DOI
|
5 |
National registry system for cervical cancer in Vietnam (2007). Statistics of provincial prevalence of cervical cancer.
|
6 |
Pham THA (2001). Cancer registration in Vietnam. Asian Pac J Cancer Prev, 2, 85-90.
|
7 |
Pham THA, Nguyen TH, Herrero R, et al (2002). Human papilloma virus in women in the South and the North of Vietnam. Int J Cancer, 104, 213-20.
|
8 |
Walboomers J, Jacobs M, Manos M, et al (1999). Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol, 189, 12-9.
DOI
|
9 |
Clifford G, Smith J, Plummer M, et al (2003). Human papillomavirus types in invasive cervical cancer worldwide: a meta-analysis. Br J Cancer, 88, 63-73.
DOI
|
10 |
Dunne EF, Unger RE, Sternberg M (2007). Prevalence of HPV infection among females in the United States. JAMA, 297, 813-9.
DOI
|